MaaT Pharma Reports Financial Results for the Third Quarter 2026
Regulatory News:MaaT Pharma (EURONEXT:MAAT — the “Company”), a late-stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today reported its cash position and…